May 24, 2017 12:01 PM EDT

ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies

→ The European Commission granted orphan drug designation to miRagen’s $MGEN MRG-106 for the treatment of cutaneous T-cell lymphoma …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Im­muno­Gen gets $25M up­front for ADC ther­a­py; mi­Ra­gen adds Eu­ro­pean or­phan drug des­ig­na­tion; Pierre Fab­re buys some pre­clin­i­cal im­munother­a­pies